Kenvue Inc. (KVUE) Stock Price & Analysis

Kenvue Inc. (KVUE) rose 2.11% to USD 17.92 as of June 9, 2026 at 22:36 UTC, according to Nexqual real-time market data.

KVUE last closed at USD 17.55; the session ranged USD 17.44–17.94 on volume of 17,245,416 shares. Market capitalization is $34.41B, with a 52-week range of USD 14.02–22.87 (NYQ). Source: Nexqual, June 9, 2026 at 22:36 UTC.

Key Statistics (as of June 9, 2026 at 22:36 UTC)

Technical Analysis (KVUE)

Nexqual's technical model rates KVUE "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 22:36 UTC.

Analyst Ratings (KVUE)

Wall Street analysts rate KVUE "Hold" based on 12 analysts, with a mean price target of USD 19.5 (range USD 18–23), per Nexqual as of June 9, 2026 at 22:36 UTC.

Earnings (KVUE)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Financials & Fundamentals (KVUE)

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Financial Health Score (KVUE)

Nexqual rates Kenvue Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:36 UTC.

Ownership (KVUE)

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Leadership (KVUE)

Kenvue Inc. is led by Kirk L. Perry (age 58), CEO & Director, per Nexqual as of June 9, 2026 at 22:36 UTC.

Major Backers & Investors (KVUE)

Notable institutional backers of Kenvue Inc. include FMR, LLC, Pentwater Capital Management Lp, Massachusetts Financial Services Co., according to Nexqual as of June 9, 2026 at 22:36 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 22:36 UTC.

From Kenvue Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)

Key Strengths & Strategy (as disclosed to the SEC)

• U.S. federal authorities, including the FDA, the Federal Trade Commission (the "FTC"), the Consumer Product Safety Commission (the "CPSC"), the Occupational Safety and Health Administration (the "OSHA"), the Environmental Protection Agency (the "EPA"), and the Drug Enforcement Administration (the "DEA"), regulate various aspects of our business, along with parallel authorities at the state and local levels and comparable authorities in other jurisdictions.
• Noncompliance with these laws may result in penalties or other regulatory action and related reputational harm. 11 Drug Products In order to market and sell a new drug product in the United States, a manufacturer must 1) file a New Drug Application ("NDA") that shows the quality, safety, and effectiveness of the new drug, 2) file an Abbreviated NDA that demonstrates the equivalence of a generic product to another company's branded drug product, or 3) comply with the FDA's monograph system.
• In addition, certain of our OTC products, including certain Imodium ® , Motrin ® , Pepcid ® , and Zyrtec ® products, are approved by the FDA through the NDA process rather than through the monograph system.
• Cosmetics A number of our products marketed in the United States, including many of our products in the Skin Health and Beauty segment, are considered cosmetics regulated by the FDA through the Federal Food, Drug, and Cosmetic Act and the Fair Packaging and Labeling Act.

Partnerships

• We are a digital modern marketing company, and we collaborate with celebrities, influencers, and healthcare professionals to amplify brand awareness and product innovations.
• The majority of our distribution centers are operated in partnership with expert third-party operators in order to leverage their scale, expertise, and technology platforms.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:36 UTC. This page is informational and not investment advice.